MYNZ

Insider Trades

Name	Value	Action	Price	Current Price
Donahue Kevin Michael10 Percent Owner $259B643.9k shares BuyOct 17, 2025 $402,000.00 --
Donahue Kevin Michael10 Percent Owner $1.0M685k shares BuyOct 17, 2025 $1.51 --

Trade MYNZ

About Mainz Biomed B.V.

Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.

CEO: Guido Baechler
IPO Date: Nov 5, 2021

Market Data

Open: $3.65
High: $3.72
Low: $3.38
Volume: 6M
52W High: $5.34
52W Low: $0.5476

Valuation

Market Cap: $15M
Enterprise Value: $23M

Financials

Free Cash Flow: $-11M
Revenue: $537k
Net Income: $-16M
Cash: $889k
Debt: $2.6M

Events

EarningsApr 14

EPS est. -1.01